Aims: To discuss the current methodological and conceptual difficulties inherent in characterizing the emotional manifestations of neurodegenerative disease through critically reviewing depression as a manifestation of idiopathic Parkinson’s disease (PD).

Methods: Selective literature review of the neurobiological, psychological, and physical basis of depressive symptoms in PD from 1993–2003, with reference to key earlier articles.

Conclusions: There are difficulties in defining the syndromes of PD itself as well as depression in PD. The use of more conceptually reductionistic definitions of emotion and behavior in comprehensive longitudinal studies of the natural history of PD is recommended.

Keywords: Parkinson’s disease, depression, nosology

Introduction
We wish to explore some of the epistemological and methodological issues regarding the phenomenology, nosology, and ultimately, the investigation of neuropsychiatric disorders. In particular, we will focus on the constraints of applying standardized criteria for depression (WHO 1992; APA 2000), developed for the relatively neurologically healthy, to emotional disorders such as depression in neurodegenerative disease. As a prototypical neuropsychiatric disorder, Parkinson’s disease affects cognition, emotion, autonomic, and motor aspects of the nervous system. In this critical review, we seek to focus on the phenomenon of depression in Parkinson’s disease, with a view to better appreciating the difficulties that face those seeking to investigate the nature of emotional disorders in neurodegenerative disease. We acknowledge that other syndromes within Parkinson’s disease, such as psychosis, may also lend themselves to such exploration, as may other neuropsychiatric disorders such as Alzheimer’s disease and vascular dementias. For brevity, and because the arguments may be similarly applied to a lesser or greater degree in these other conditions, we have focused on depression in Parkinson’s disease.

Difficulties in characterizing the emotional manifestations of Parkinson’s disease
Parkinson’s disease is an age-related neurodegenerative disorder characterized by the physical manifestations of resting tremor, rigidity, bradykinesia, and postural instability (Gerl et al 1999; Schrag et al 2002). Despite Parkinson’s original observation of preservation of the mental faculties, it is now well recognized that
there are cognitive and emotional manifestations of the disease (Waters 1998). Depression has been described as the major psychological complication, with a prevalence of 2%-70% in those suffering from PD (Hoogendijk et al 1998; Becker et al 2002). Indeed, when matched for comparable degrees of physical disability with disorders such as osteoarthritis and diabetes, a higher prevalence of depressive disorders were found in the PD group in a large Danish cohort (Murray 1996; Nilsson et al 2001).

However, the characterization of the emotional and cognitive consequences of cerebral neurodegenerative disease remains fraught with misconceptions and uncertainties. Heretofore, the delineation of the psychiatric consequences of neurodegenerative disease has involved surveying patients suffering from neurodegenerative disease with standardized psychiatric diagnostic instruments to characterize psychiatric syndromes described as depression, mania, anxiety, and psychosis. Such an approach has limitations, particularly in Parkinson’s disease (PD), due to diagnostic uncertainties in differential diagnosis of idiopathic PD (the major parkinsonian syndrome) from other etiologically distinct parkinsonian syndromes; manifestations of PD which may present as behavioral mimics or phenocopies of depression (Berrios et al 1995) such as apathy; issues of circular/self-referential classification through application of diagnostic criteria for depression in otherwise healthy persons to diagnose depression in PD; and the ongoing debate as to whether a distinct depression in idiopathic PD exists. Indeed, the conceptual challenge of depression in PD has recently been discussed from a semantic and epistemological viewpoint, with reference to the pathophysiology (Leentjens and Verhey 2002). Our focus is somewhat different, and seeks to specifically explore the conceptual and methodological difficulties of defining depression in PD. In particular, we seek to explore how the application of a predetermined psychiatric paradigm of depression traps us in a conceptual oubliette.

**Diagnostic uncertainty in parkinsonian syndromes**

Parkinsonism itself is a protean entity and aside from idiopathic Parkinson’s disease (PD) may result from Parkinson’s-plus syndromes such as corticobasal ganglionic degeneration, multiple systems atrophy, progressive supranuclear palsy, or Lewy-Body dementia (Poewe and Wenning 2002). Furthermore, Parkinsonism may be secondary to toxic insults, infections, cervical/cerebral trauma (such as a component of dementia pugilistica), or cerebrovascular disease. Finally, other unrelated movement disorders may masquerade as Parkinson’s disease, such as Huntington’s disease, Wilson’s disease, or familial olivopontocerebellar atrophy.

In addition, a specific etiopathogenesis has not been identified with putative causative factors including genetic factors, toxins, oxidative stress, mitochondrial dysfunction, glutamergic excitotoxicity, glial, neurotrophic, and apoptosis being postulated (Olanow and Tatton 1999).

The relative paucity of in vivo, clinically valid, available, and specific biomarkers for PD renders differential diagnosis difficult, as does the absence of specific clinical features that may differentiate idiopathic PD from other Parkinsonian syndromes (Gelb et al 1999). Idiopathic Parkinson’s disease may therefore be misdiagnosed at rates approaching 20%-30% (Poewe and Wenning 2002); and at autopsy, characteristic neuropathological changes are only confirmed in 75% of cases (Gelb et al 1999). Functional neuroimaging techniques such as assessment of striatonigral dopaminergic activity using I$^{123}$ Beta-CIT or I$^{123}$ FP-CIT single photon emission computerized tomography (SPECT), a ligand for the dopamine transporter in the caudate and putamen, have utility in confirming the diagnosis of Parkinson’s disease (Duchesne et al 2002; Piccini and Whone 2004). The ratio of caudate to putamen activity shows a 50% reduction of I$^{123}$ Beta-CIT binding in the putamen by disease presentation in PD, with a relatively poorly differentiating relative reduction of binding in the caudate for atypical Parkinsonian syndromes (Brucke et al 1997; Gerschlager et al 2002; Piccini and Whone 2004). Positron emission tomography (PET) has relatively less clinical utility due to the requirement of a cyclotron for generation of the radioisotopes used. Of the PET modalities, $^{18}$F-dopa PET has the most utility, demonstrating loss of up to 50% of normal $^{18}$F-dopa (a marker of accumulation and metabolism of levodopa) uptake in caudal putamen; however, again differentiation from progressive supranuclear palsy, multiple systems atrophy, or corticobasal degeneration remains problematic (Antinoni et al 1997; Ghaemi et al 2002; Piccini and Whone 2004).

Leentjens and Verhey (2002), assert that Parkinson’s disease is a distinct disease entity in contradistinction to psychiatric syndromal diagnosis such as depression. In contrast, we assert that in clinical practice Parkinson’s disease is a syndrome rather than a disease, given that we
are unable to ascertain neurobiological data to confirm the diagnosis. This is supported by the relative lack of valid, specific biomarkers such as functional brain neuroimaging and data on misdiagnosis cited above. Furthermore, idiopathic PD is ipso facto of unknown etiopathogenesis, and clinical features do not necessarily correlate with classical neuropathology. We therefore argue that PD and depression both represent syndromal constructions. However, the core syndrome of idiopathic PD is associated with characteristic neuropathological changes postmortem, and there has been speculation on what neurophysiological, neurochemical, and neuroanatomical alterations may serve as the substrate for possible disturbances of cognition and emotion in PD. Here we find ourselves dashed upon the shores of psychiatric syndromal diagnosis, as depression and other psychiatric complications of PD have been heretofore defined using standardized criteria for psychiatric diagnosis designed for neurologically intact and otherwise healthy persons.

Self-referential or circular definitions of depression in PD

In current psychiatric nosology, depression has been defined by operationalized diagnostic criteria formulated by the American Psychiatric Association (DSM-IV) (APA 2000) and the World Health Organization (ICD-10) (WHO 1992) classification of mental disorders. Thus, the diagnosis of major depressive disorder is predicated on the presence of five or more symptoms: low mood, anhedonia, sleep disturbances, weight loss, psychomotor agitation, fatigue, guilt, poor concentration, and suicidal ideation present for more than two weeks (DSM-IV) (APA 2000). This syndromal diagnosis has little reference to putative etiopathogenesis or clinical course apart from a duration specific qualifying period and mandatory exclusion factors (Leentjens and Verhey 2002). The assessment of depression in clinical research has been made by means of structured clinical interviews and/or assessment via depression rating scales based on these criteria.

These extant criteria and methods for assessing depression have been applied for the diagnosis of “depression” in PD, generating an inherent circularity. That is, one can only characterize depression in PD within the confines of the construct of DSM-IV/ICD-10 major depression, thereby precluding us from identifying possibly unique features of the emotional manifestations of PD. Indeed, this type of circularity is not new in the neuropsychiatric literature and has been remarked upon with the definition of vascular cognitive impairment upon a paradigmatic definition derived from Alzheimer’s disease (Looi and Sachdev 1999).

Incidence of parkinsonism in persons with depression

Several studies have identified that depression often predates a diagnosis of PD, providing increasing evidence for a common etiology of the two disorders. There have been several studies that have shown depression to be a risk factor for the development of PD (Nilsson et al 2001; Schuurman et al 2002), and several retrospective case control studies showing that PD is preceded by a prodromal phase, characterized by an increased incidence of mood disorders (Gonera et al 1997; Shiba et al 2000). However, the most substantial evidence has come from an epidemiological study, where the lifetime incidence of depressive disorder was calculated for patients, from a general practice based register, until their diagnosis of PD and compared with that of a matched control population from the same register (Leentjens et al 2003). This study found that at the time of their diagnosis of PD, 9.2% of the patients had a history of depression, compared with 4% of the control population. In addition, Nilsson et al (2002), via analysis of a Danish register, found a significant increased risk for hospitalization because of depression in patients with PD compared with subjects with osteoarthritis or diabetes mellitus, providing further support for the hypothesis that depression in patients with PD is a consequence of a shared pathophysiological basis.

Neurobiological basis of cognitive and emotional symptoms behaviorally equivalent to depression in PD

The known neuropathology of PD comprises age-related degeneration of dopaminergic neurons in the substantia nigra pars compacta associated with intracytoplasmic aggregates of alpha-synuclein known as Lewy bodies (Olanow and Tatton 1999). These neurodegenerative changes and Lewy bodies are also found in the locus coeruleus, nucleus basalis of Meynert, hypothalamus, cerebral cortex, brainstem motor nuclei, and autonomic nervous system (Berg et al 1999; Olanow and Tatton 1999). As would be expected from such widespread neuropathology, the PD process may potentially
impact upon a number of structures, circuits, and neurotransmitter function, yielding widespread effects on cognition and emotion.

The role of neurochemical changes in PD in causing depressive symptomatology remains largely speculative. It is important to emphasize that the majority of data pertain to neurochemical and neuropathological changes in Parkinson’s disease per se, rather than in depressed Parkinson’s disease patients. We have summarized the relevant findings in Tables 1 and 2, with Table 1 describing neurochemical changes and Table 2 describing neuropathological changes (Mann and Yates 1983; Cash et al 1984; Mayeux et al 1984, 1986; Kostic et al 1987; Turkka et al 1987; Chan-Palay and Asan 1989; Pachetti et al 1990; Paulus and Jellinger 1991; Kuhn et al 1996; Bertrand et al 1997; Engelborgh et al 2003). There are conflicting data on the serotonin metabolite 5-hydroxy-indoleacetic acid, with some studies showing decreased levels in depressed PD patients (Mayeux et al 1984, 1986; Kostic et al 1987) and others equally showing no significant differences (Kuhn et al 1996). The evidence for the effects of dopamine and depression has been similarly lacking (Kuhn et al 1996). At best the role of noradrenaline is speculative at present.

Putative neuroanatomical substrates have been based on neuropsychological evidence of frontal system dysfunction (Starkstein and Mayberg 1992; Murray 1996; Schrag et al 2001; Slaughter et al 2001), frontomesial pathology (Starkstein and Petracca 1998), and frontal system hypometabolism on SPECT and PET (Becker et al 2002). Frontal-executive dysfunction is the most common

**Table 1** Neurochemical changes in Parkinson’s disease (PD)

| Authors          | Sample characteristics                                                                 | Dopamine | Noradrenaline | Serotonin                                                                 |
|------------------|------------------------------------------------------------------------------------------|----------|---------------|---------------------------------------------------------------------------|
| Engelborgh et al | Comparison of CSF biogenic amines in PD vs aged matched controls                          | Dopamine metabolite (DOPAC) significantly lower in PD compared with control | No statistically significant change in CSF NA levels between PD and controls | SHT was significantly higher and SHIAA was significantly lower in PD group with SHIAA/SHT ratio lower in PD group reflecting decreased SHT catabolism |
| Kuhn et al 1996  | Comparison of de novo depressed (PDd) and non-depressed (PDn) Parkinson’s disease patients | No significant difference between CSF levels of dopamine and its metabolites between PDd and the PD groups | No significant difference between CSF levels of noradrenaline and its metabolites between the PDd group and PD group | No significant difference of SHIAA between the PDd group and the PD group |
| Pacchetti et al 1990 | Comparison between depressed and non-depressed PD patients PD (n) = 52, of which 20 are de novo patients | No significant difference in SHIAA CSF between PDd and PD |
| Kostic et al 1987 | Comparison between depressed and non-depressed PD patients PD (n) = 52, of which 20 are de novo patients | Levels of CSF NA was not significantly different between PD and aged matched controls |
| Turkka et al 1987 | Comparison between depressed and non-depressed PD patients. 10-day dopamine-free period PD (n) = 49 | Levels of CSF 5HIAA was lowest in PDd than in PD |
| Mayeux et al 1986 | Comparison between depressed and non-depressed PD patients. 10-day dopamine-free period PD (n) = 49 | Levels of CSF 5HIAA was lowest in PDd than in PD |
| Mayeux et al 1984 | Comparison of de novo depressed (PDd) and non-depressed (PDn) Parkinson’s disease patients PD (n) = 52, of which 20 are de novo patients | Data found that CSF 5HIAA content of PDd was lower than PD |

**Abbreviations:** CSF, cerebrospinal fluid; NA noradrenaline.
Depression in Parkinson’s disease

Memories, word-list generation, organization of complex visual copying, and shifting of cognitive set (Mahieux et al. 1998; Cummings and Mega 2003). Dysfunction in these systems could result in symptomatology consistent with depression such as executive dysfunction and impaired concentration. Furthermore, there is emerging evidence that non-verbal emotional information processing is impaired early in PD (Dujardin et al. 2004) and that this may contribute to neuropsychological deficit demonstrated in PD (Levy et al. 2002; Cummings and Mega 2003) and its occurrence is predictive of dementia (Mahieux et al. 1998; Levy et al. 2002). The deficits described comprise problems with memory retrieval, word-list generation, organization of complex visual copying, and shifting of cognitive set (Mahieux et al. 1998; Cummings and Mega 2003). Dysfunctional in these systems could result in symptomatology consistent with depression such as executive dysfunction and impaired concentration. Furthermore, there is emerging evidence that non-verbal emotional information processing is impaired early in PD (Dujardin et al. 2004) and that this may contribute.

Table 2 Neuropathological changes in Parkinson’s disease (PD)

| Authors               | Design                           | Substantia nigra | Results                                                                 |
|-----------------------|----------------------------------|------------------|-------------------------------------------------------------------------|
| Mann and Yates 1983   | PD (n) = 8. PD cases not recruited for depression. |                  | LC degeneration in PD cases. Greater adrenergic cell loss in those with dementia relating to the disease process. |
| Cash et al 1984       | PD (n) = 20. Thirteen of the PD patients had dementia. Patients not recruited for depression. Unable to establish diagnosis of depression in any of the cases. |                  | Increased adrenergic receptors in the prefrontal cortex of parkinsonian patients. Greater increases in alpha1 adrenergic receptors were noted in PD patients with dementia. Suggestion that the increase in adrenergic receptors is a compensatory mechanism in relation to a decrease in cell loss. |
| Chan-Palay et al 1989 | PD (n) = 7. Post-mortem study of heterogenous PD group. Chronic elderly PD patients, not specifically recruited for depression. Five of the PD patients had rapidly progressive dementia MMSE 0–5, two of which were atypically depressed and were not L-dopa responsive. |                  | LC neuronal degeneration and cell loss. Decreased LC length. Greater degeneration of LC was noted in the PDd. |
| Paulus and Jellinger 1991 | Post-mortem studies of elderly PD patients some with comorbid dementia, depression, and psychosis. Diagnosis of depression and psychosis was retrospective based on clinical notes. | PD patients significant cell loss compared with controls. | Reduced cell count in the LC of PD compared with controls. PD (n) = 37 Controls (n) = 12 No difference in LC count and density in between depressed and non-depressed PD. Reduced cell count in PD compared with controls. |
| Bertrand et al 1997   | Post-mortem study of 21 PD cases. One case was known to have severe dementia. Cases did not differentiate between depressed and non-depressed patients. |                  | Significant loss of adrenergic neurons in LC. LC neuronal loss increases with disease duration. Significantly decreased LC neurons in the patient with severe dementia. |

Abbreviations: MMSE, Mini-Mental State Examination.
to a presentation consistent with depression. The role of the basal limbic system and associated brainstem nuclei dysfunction in contributing to depressive symptoms remains more speculative at this stage, but potentially could be responsible for deficits in mood, behavior, and sleep (Berg et al 1999; Becker and Berg 2001).

Disruptions of circuit connectivity in the brain have been postulated as a possible mechanism for post-stroke depression, in the absence of clear evidence of neurotransmitter dysfunction (Herrmann et al 1995). The pathways implicated traverse the basal ganglia and involve the intricate white matter loops interconnecting the structures known as the frontosubcortical circuits, with resultant changes in cognition and emotion, and have been implicated in major depression in otherwise healthy persons (Austin et al 2001). In addition, dysfunction in autonomic circuitry, as evinced by orthostasis and postural instability and its association with depression, has been demonstrated (Berrios et al 1995; Schrag et al 2001). Furthermore, disruption of these frontosubcortical circuits results in frontal-executive dysfunction, such as is found in vascular cognitive impairment (Looi and Sachdev 2000) and which has been noted in uncomplicated depression (Austin et al 2001). It is possible, albeit speculative, that remote upstream or downstream effects described as diaschisis may result from neurodegeneration in the basal ganglia and associated circuitry in PD, and thereby, may contribute to local or distant changes in motor, cognitive, and affective functions resembling depression. This would explain the occurrence of frontal-executive dysfunction, associated depressive symptomatology, and anxiety symptoms in PD. It therefore follows that the core neurobiological changes of PD may result in a neurobehavioral syndrome resembling depression (Cummings and Mega 2003).

**Manifestations of PD as behavioral mimics or phenocopies of depression**

Behavioral manifestations of PD such as agitation, anxiety, anhedonia, apathy, and psychosis may individually or synergistically serve as phenocopies of depression (Berrios et al 1995). Agitation, apathy, and anxiety have been identified as being highly prevalent in epidemiological surveys of persons with PD (Aarsland et al 1999). These behavioral changes may be misidentified as depression due to their resemblance to clinical manifestations of DSM-IV major depression. Apathy refers to reduced interest and participation in normal purposeful behavior, lack of initiative, and indifference with affective blunting (Pluck and Brown 2002). Apathy has now been recognized as a prominent and important manifestation of the emotional consequences of PD, having been demonstrated to be more prevalent in those with PD compared with equally disabled patients with osteoarthritis in the absence of differences in personality traits or cognition (Pluck and Brown 2002). Up to 40% of patients with PD may experience significant anxiety, a higher than expected level for age-matched controls and that this may be clustered into panic disorder, phobias, and generalized anxiety disorder (Starkstein et al 1993; Walsh and Bennett 2001). In particular, generalized anxiety may closely resemble agitated depression via restlessness (which can be interpreted as psychomotor agitation), rumination on trivial concerns, and seeking of reassurance. Furthermore, panic attacks may also mimic agitated depression. Anhedonia itself has been identified as a prominent neuropsychiatric symptom of PD, in the absence of association with mood (Isella et al 2003) and representing a deficit in novelty seeking behavior. Thus, anhedonia may represent part of the core neuropsychiatric disturbance in PD, secondary to deficits in the dopamine reward circuits, and may masquerade as depression (Menza and Mark 1994). In addition, psychosis may also occur frequently in PD and may therefore mimic a psychotic depression.

The diagnostic confusion is further exacerbated by cognitive and physical manifestations of PD which also resemble features of depression, such as impaired concentration, cognitive/psychomotor slowing, bradykinesia, reduced libido, fatigue, and sleep disturbance (Happe et al 2001; Leentjens and Verhey 2002; Pluck and Brown 2002; Schuurman et al 2002; Lieberman 2003). There may be somatic preoccupations with genuine physical complications such as dizziness, tinnitus, epigastric pain, headaches, bladder, and bowel disturbances (Leentjens and Verhey 2002).

The idea that the physical and behavioral manifestations of PD may resemble depression and is a neurobiological manifestation of the disorder is not new (Cummings and Mega 2003). Indeed, Berrios and colleagues (1995) concluded that anxiety and depression in a proportion of PD patients was a behavioral phenocopy induced by autonomic dysfunction (Lerner and Whitehouse 2002). However, we would broaden this concept to include the range of cognitive, emotional, and physical symptoms of PD that may mimic the depressive syndrome.
A specific syndrome of low mood in PD?

It would seem self-evident that depression could be conceptualized as an understandable reaction to the suffering caused by PD. However, such an approach has been already identified as being overly simplistic and is contradicted by the lack of association between disease factors and progression with the degree of severity of depression (Starkstein et al 1989; Troster et al 1995; Lerner and Whitehouse 2002).

Much has been written about a distinct syndrome of low mood or depression characteristic to PD, which is somehow distinct from the conventional definition of “idiopathic” (for want of a better term) depression (Cummings and Masterman 1999; Stocchi and Brusa 2000; Myslobodsky et al 2001; Slaughter et al 2001; Yamamoto 2001; Cummings and Mega 2003). This distinction has proved difficult to demonstrate, and we suggest that this is due to a priori application of conventional criteria for depression to the depressive syndrome of PD, thereby constraining the data obtained as opposed to a more descriptive approach such as using an inventory of psychiatric syndromes. Some authors have identified that depressive cognitions are less prevalent in PD than in idiopathic depression (Yamamoto 2001). Others have identified a greater preponderance of somatic symptoms (sleep disturbance, decreased appetite, and anhedonia), dysphoria, suicidal ideation, and a qualitative difference in the nature of the sadness (Slaughter et al 2001). A majority have stated that anxiety symptoms are prominent, there is a lack of mood-congruent psychosis and there are low suicide rates despite a high frequency of suicidal ideation (Cummings and Masterman 1999; Stocchi and Brusa 2000; Myslobodsky et al 2001; Slaughter et al 2001; Yamamoto 2001). Is anxiety being misdiagnosed as depression? Does the lack of suicidal behavior reflect a syndrome of apathy? What are the comorbidity rates of apathy, anxiety, and agitation in PD? Despite these questions, others maintain that there are no characteristic differences between depression in PD and idiopathic depression in older adults (Erdal 2001).

Climbing up the ladder

We would therefore conclude that Parkinson’s disease is, in a clinical setting, a syndrome of considerable heterogeneity. Extant psychiatric diagnostic criteria for depression so closely approximate the clinical cognitive, emotional, and physical manifestations of the PD syndrome so as to render the syndromes indistinguishable in part or whole. How are clinicians, especially in primary care, to struggle with the vicissitudes of diagnosis of depression in PD? The putative neurobiological basis of idiopathic PD may be expected to result in emotional consequences consistent with major depression as currently defined. Phenomenological and clinical understanding of the cognitive and emotional consequences of PD, such as depressive symptoms, can best be advanced by careful integrated longitudinal study of the physical, cognitive, and emotional consequences of PD syndromes. Such longitudinal studies should use more conceptually reductionistic diagnostic criteria for emotional consequences such as apathy, specific anxiety syndromes, anhedonia, insomnia, and psychosis as well as the broader construct of “depression” to better characterize these core phenomena without being constrained to an a priori conceptualization of depression. However, it is not entirely pragmatic to eschew the guideposts of description of emotional distress provided by conventional psychiatric nosology, as these provide at least a means of discourse regarding emotional distress and because research to date has utilized such diagnostic criteria to describe these phenomena. Practically, therefore, we suggest inclusion of descriptors of more discrete cognitive and emotional phenomena as well as including classifications according to standardized criteria for depression in longitudinal studies of the natural evolution of Parkinson’s disease, a process which has been possible in the analogous investigation of the emotional and cognitive aspects of cerebrovascular disease (Sachdev et al 2004).

We would propose such longitudinal studies of depression in PD should:
1. Examine patients with early-stage PD;
2. Comprehensively characterize their physical, cognitive, and emotional function using measures of motor dysfunction, autonomic function, disability, anxiety, apathy, anhedonia, and cognitive function;
3. In parallel, collect information on depression according DSM-IV/ICD-10 psychiatric classifications;
4. Examine cognitive and emotional processing of anxious and depressive thinking in PD;
5. Utilize structural and functional brain neuroimaging to assist in identifying the neuroanatomical and neurochemical bases of depressive symptoms in PD.

In this way, we may free ourselves from the conceptual oublie of a predetermined concept of depressive symptomatology in describing the cognitive and emotional manifestations of Parkinson’s disease.
Acknowledgments
Thanks to Ms Lee-Fay Low for editorial comments and Professor Sergio Starkstein for valuable advice. This research was generously supported in part by the ACT Health and Medical Research Support Program; Canberra Hospital Salaried Specialists Private Practice Fund Grant to Drs Looi and R Kumar; a New South Wales Institute of Psychiatry Research Training Fellowship to Ms Ruzich; a Young Researcher Training Award from the Board of Research, Royal Australian and New Zealand College of Psychiatrists to Dr Matias; and Australian-American Fulbright Commission Support as a J William Fulbright Scholar to UCLA for Dr Looi.

References
Aarsland D, Larsen JP, Lim NG, et al. 1999. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry, 67:492–6.
Antinoni A, Leenders KL, Votolop P. 1997. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain, 120:2187–95.
[APA] American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). Washington: APA.
Austin MP, Mitchell P, Goodwin GM. 2001. Cognitive deficits in depression: possible implications for functional neuroepithiology. Br J Psychiatry, 178:200–6.
Becker G, Berg D. 2001. Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound. Mov Disord, 16:23–32.
Becker G, Muller A, Braun S, et al. 2002. Early diagnosis of Parkinson’s disease. J Neurol, 249(Suppl 3):III:40–8.
Berg D, Supprian T, Hofmann E, et al. 1999. Depression in Parkinson’s disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol, 246:1186–93.
Berrios GE, Campbell C, Politynska BE. 1995. Autonomic failure, depression and anxiety in Parkinson’s disease. Br J Psychiatry, 166:789–92.
Bertrand E, Lechowicz W, Szpak G, et al. 1997. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson’s disease. Folia Neuropathol, 35:80–6.
Brucke T, Asenbaum S, Pirker W. 1997. Measurement of dopaminergic degeneration in Parkinson’s disease with [1123] bet-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl, 50:9–24.
Cash R, Ruberg M, Raisman R, et al. 1984. Adrenergic receptors in Parkinson’s disease. Brain Res, 322:269–75.
Chan-Palay V, Asan E. 1989. Alterations in catecholamine neurons in the locus coeruleus of senile dementia of Alzheimer’s type and in Parkinson’s disease with and without dementia and depression. J Comp Neurol, 287:373–92.
Cummings JL, Masterman DL. 1999. Depression in patients with Parkinson’s disease. Int J Geriatr Psychiatry, 14:711–18.
Cummings JL, Mega MS. 2003. Movement disorders. In Cummings JL, Mega MS (eds). Neuropsychiatry and behavioural neuroscience. Oxford: Oxford Univ Pr.
DUardin K, Blairy S, Defevre L, et al. 2004. Deficits in decoding emotional facial expression in Parkinson’s disease. Neuropsychologia, 42:239–50.
Engelborgh S, Marescau B, Deyn P. 2003. Amino acids and biogenic amines in the cerebrospinal fluid of patients with Parkinson’s disease. Neurochem Res, 28:1145–50.
Erdal KJ. 2001. Depressive symptom patterns in patients with Parkinson’s disease and other older adults. J Clin Psychol, 57:1559–69.
Gelb DI, Oliver E, Gilman S. 1999. Diagnostic criteria for Parkinson disease. Arch Neurol, 56:33–9.
Gerschlager W, Bencsits G, Pirker W. 2002. [1123] beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Mov Disord, 17:518–23.
Ghaemi M, Hikker R, Rudolf J. 2002. Differentiating multiple systems atrophy from Parkinson’s disease: contribution of straital and midbrain MRI volumetry and midbrain MRI. J Neurol Neurosurg Psychiatry, 73:517–23.
Gonera EG, van’t Hof M, Berger HJC, et al. 1997. Symptoms and duration of prodromal pse in Parkinson’s disease. Mov Disord, 12:871–6.
Happe S, Schrodi B, Falti M, et al. 2001. Sleep disorders and depression in patients with Parkinson’s disease. Acta Neurol Scand, 104:275–80.
Herrmann M, Bartels C, Schumacher M, et al. 1995. Poststroke depression. Is there a pathoanatomical correlate for depression in the postacute stage of stroke? Stroke, 26:850–6.
Hoogendijk WJ, Sommer IE, Tissingh G, et al. 1998. Depression in Parkinson’s disease. The impact of symptom overlap on prevalence. Psychosomatics, 39:416–21.
Iella V, Iurlaro S, Piolli R, et al. 2003. Physical anhedonia in Parkinson’s disease. J Neurol Neurosurg Psychiatry, 74:1308–11.
Kostic VS, Dijuric BM, Covicovic-Sternic N, et al. 1987. Depression and Parkinson’s disease: possible role of serotonergic mechanisms. J Neurol Neurosurg Psychiatry, 234:94–6.
Kuhn W, Muller T, Gerlach M. 1996. Depression in Parkinson’s disease: biogenic amines in CSF of “de novo” patients. J Neural Transm, 103:1441–5.
Leentjens AF, van den Akker M, Mestemakers JF, et al. 2003. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord, 18:141–18.
Leentjens AF, Verhey FR. 2002. Depression and Parkinson’s disease: a conceptual challenge. Acta Neuropsychiatrica, 14:147–53.
Lerner AJ, Whitehouse PJ. 2002. Neuropsychiatric aspects of dementias associated with motor dysfunction. In Yudofsky SC, Hales RE (eds). American psychiatric publishing textbook of neuropsychiatry and clinical neurosciences. Washington: American Psychiatric Publ.
Levy G, Jacobs DM, Tang M-X, et al. 2002. Memory and executive function impairment predict dementia in Parkinson’s disease. Mov Disord, 17:1221–6.
Lieberman A. 2003. Depression in Parkinson’s disease. Florida: National Parkinson Foundation.
Looi J, Sachdev P. 1999. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology, 53:670–8.
Looi J, Sachdev P. 2000. Vascular dementia as frontal subsclortal system dysfunction. Psychol Med, 30:997–1003.
Mahieux F, Fenelon G, Flahaut A, et al. 1998. Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry, 64:173–83.
Mann DMA, Yates PO. 1983. Pathological basis for neurotransmitter changes in Parkinson’s disease. Neuropathol Appl Neurobiol, 9:3–19.
Mayeux R, Stern Y, Cote L, et al. 1984. Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology, 34:642–6.
Mayeux R, Stern Y, Williams JBW, et al. 1986. Clinical and biochemical features of depression in Parkinson’s disease. Am J Psychiatry, 143:756–9.
Menza MA, Mark MH. 1994. Parkinson’s disease: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci, 6:165–9.
Murray JB. 1996. Depression in Parkinson’s disease. J Psychol, 130:659–67.
Depression in Parkinson’s disease

Myslobodsky M, Lalonde FM, Hicks L. 2001. Are patients with Parkinson’s disease suicidal? *J Geriatr Psychiatry Neurol*, 14:120–4.

Nilsson FM, Kessing LV, Bolwig TG. 2001. Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. *Acta Psychiatr Scand*, 104:380–6.

Nilsson FM, Kessing LV, Sorensen TM, et al. 2002. Major depressive disorder in Parkinson’s disease: a register-based study. *Acta Psychiatr Scand*, 106:202–11.

Olanow C, Tatton WG. 1999. Etiology and pathogenesis of Parkinson’s disease. *Annu Rev Neurosci*, 22:123–44.

Pachetti G, Bruggia P, Marignoni E, et al. 1990. Depression and Parkinson’s disease: association or identity? *New Trends Clin Neuropharmacol*, 4:13–26.

Paulus W, Jellinger K. 1991. The neuropathological basis of different clinical subgroups of Parkinson’s disease. *J Neuropathol Exp Neurol*, 50:743–55.

Piccini P, Whone A. 2004. Functional brain imaging in the differential diagnosis of Parkinson’s disease. *Lancet Neurol*, 3:284–90.

Pluck GC, Brown RG. 2002. Apathy in Parkinson’s disease. *J Neurol Neurosurg Psychiatry*, 73:636–42.

Poewe W, Wenning G. 2002. The differential diagnosis of Parkinson’s disease. *Eur J Neurol*, 9:23–30.

Sachdev PS, Brodaty H, Valenzuela MJ, et al. 2004. The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. *Neurology*, 62:912–19.

Schrag A, Ben-Shlomo Y, Quinn N. 2002. How common are complications of Parkinson’s disease? *J Neurol*, 249:419–23.

Schrag A, Jahanshahi M, Quinn NP. 2001. What contributes to depression in Parkinson’s disease? *Psychol Med*, 31:65–73.

Schuurman AG, van den Akker MP, Ensink KT, et al. 2002. Increased risk of Parkinson’s disease after depression: a retrospective cohort study. *Neurology*, 58:1501–4.

Shiba M, Bower JH, Maraganore DM, et al. 2000. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. *Mov Disord*, 15:669–77.

Slaughter JR, Slaughter KA, Nichols D, et al. 2001. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. *J Neuropsychiatry Clin Neurosci*, 13:187–96.

Starkstein S, Mayberg HS. 1992. A prospective longitudinal study of depression, cognitive decline and physical impairments in patients with Parkinson’s disease. *J Neurol Neurosurg Psychiatry*, 55:377–82.

Starkstein S, Petraea G. 1998. Depression in classic versus akinetic rigid Parkinson’s disease. *Mov Disord*, 13:29–33.

Starkstein SE, Berthier ML, Bolduc PL. 1989. Depression in patients with early versus late onset of Parkinson’s disease. *Neurology*, 39:1441–5.

Starkstein SE, Robinson RG, Leiguardia R. 1993. Anxiety and depression in Parkinson’s disease. *Behav Neurol*, 6:151–4.

Stocchi F, Brusa L. 2000. Cognition and emotion in different stages and subtypes of Parkinson’s disease. *J Neurol*, 247(Suppl 2):II/14–21.

Troster AI, Stalp LD, Paolo AM. 1995. Neuropsychological impairment in Parkinson’s disease with and without depression. *Arch Neurol*, 52:1164–9.

Turkka JT, Juurjarvai KK, Myllyla VV. 1987. Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenolglycol in Parkinson’s disease. *Eur Neurol*, 26:29–34.

Walsh K, Bennett G. 2001. Parkinson’s disease and anxiety. *Postgrad Med J*, 77:89–93.

Waters C. 1998. Diagnosis and management of Parkinson’s disease. California: Professional Communications.

[WHO] World Health Organization. 1992. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: WHO.

Wittgenstein L. 1974. Tractatus Logico-Philosophicus. London: Routledge & Kegan Paul.

Yamamoto M. 2001. Depression in Parkinson’s disease: its prevalence, diagnosis, and neurochemical background. *J Neurol*, 248(Suppl 3):III/5–11.
